Antifungal Antagonism Screening

NCATS药物收藏（NPC）目前批准的药物将进行筛选，以确定那些减少四个主要的人类真菌病原体（C。albicans、假丝酵母C. glabrata、光叶隐翅虫C. neoformans和A.烟曲霉属）到最常用的抗真菌药物类别（唑类、阿替霉素B和棘白菌素。这将确定可能破坏当前使用的抗真菌药物的临床疗效的药物列表。 作为一个分支，ETB与NIH和校外研究人员建立并保持了110多个积极的合作关系，促进了整个人类疾病谱的药物发现工作。

The NCATS Pharmaceutical Collection (NPC) of currently approved drugs will be screened to identify those that reduce the susceptibility of four major human fungal pathogens (C. albicans, C. glabrata, C. neoformans and A. fumigatus) to the most commonly used classes of antifungal drugs (azoles, amphotericin B and echinocandins. This will identify a list of medications that may undermine the clinical efficacy of currently used antifungal drugs. As a branch, ETB has fostered and maintained over 110 active collaborations with both NIH and extramural investigators, facilitating drug discovery efforts across the entire spectrum of human disease.